Abstract
Dyslipidemia is one of the major risk factors for Cardiovascular Disease (CVD) that coexists with diabetes. It plays an important role in the development and progress of atherosclerosis, the underlying pathogenesis of CVD. Hyperglycemia is associated with adverse lipid profiles. An atherogenic lipid profile, consisting of high Triglycerides (TG) and small dense Low-Density Lipoprotein Cholesterol (LDL-C) and low High-Density Lipoprotein Cholesterol (HDL-C), is common not only in patients with overt diabetes but also in individuals with prediabetes. The impact of dyslipidemia on risk of CVD in patients with hyperglycemia has been extensively studied. Reduced HDL-C is well documented as an independent predictor of CVD events, the role of TG as an independent risk factor for CVD is, however, controversial. Recently, the interest to use novel parameters such as total cholesterol (TC) to HDL ratio (TC/HDL-C), non- HDL-cholesterol (non-HDL-C), apolipoprotein B (apoB) and apolipoprotein A (apoA) to assess CVD risk has increased. This chapter provides a comprehensive review of the physiology, pathophysiology, prognosis and management of dyslipidemia in individuals with different glycemic levels. The ethnic differences in occurrence of dyslipidemia are also addressed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
